Adaptive Biotechnologies Corporation (ADPT)

Adaptive Biotechnologies to Report Third Quarter 2026 Financial Results on November 4, 2026

Adaptive Biotechnologies Corp (ADPT) Stock Down 3.5% but Still Overvalued -- GF Score: 68/100

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Adaptive Biotechnologies (NASDAQ:ADPT) Hits New 52-Week High – Still a Buy?

Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of Cure

Financial Comparison: Charles River Laboratories International (NYSE:CRL) versus Adaptive Biotechnologies (NASDAQ:ADPT)

Adaptive Biotechnologies (NASDAQ:ADPT) Reaches New 1-Year High – Should You Buy?

Adaptive Biotechnologies Announces Update to NCCN Guidelines® for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ®

Adaptive Biotechnologies Corporation (ADPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Adaptive Biotechnologies to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

Algert Global LLC Has $2.83 Million Position in Adaptive Biotechnologies Corporation $ADPT

Adaptive Biotech co-founder raises $15M for new startup to rethink how AI trains on science

Dimensional Fund Advisors LP Cuts Stock Holdings in Adaptive Biotechnologies Corporation $ADPT

Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder

Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?

Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript

Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies Q2 Earnings Call Highlights

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results